Literature DB >> 21063026

Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.

Masatoshi Takagi1, Kunihiro Shinoda, Jinhua Piao, Noriko Mitsuiki, Mari Takagi, Kazuyuki Matsuda, Hideki Muramatsu, Sayoko Doisaki, Masayuki Nagasawa, Tomohiro Morio, Yoshihito Kasahara, Kenichi Koike, Seiji Kojima, Akira Takao, Shuki Mizutani.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is classically defined as a disease with defective FAS-mediated apoptosis (type I-III). Germline NRAS mutation was recently identified in type IV ALPS. We report 2 cases with ALPS-like disease with somatic KRAS mutation. Both cases were characterized by prominent autoimmune cytopenia and lymphoadenopathy/splenomegaly. These patients did not satisfy the diagnostic criteria for ALPS or juvenile myelomonocytic leukemia and are probably defined as a new disease entity of RAS-associated ALPS-like disease (RALD).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063026     DOI: 10.1182/blood-2010-08-301515

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Guest editorial: introduction of Progress in Hematology in this issue.

Authors:  Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

Review 2.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

Review 3.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Pu Li; Ping Huang; Ye Yang; Mu Hao; Hongwei Peng; Fei Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 4.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

5.  T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing.

Authors:  S Levy-Mendelovich; A Lev; E Rechavi; O Barel; H Golan; B Bielorai; Y Neumann; A J Simon; R Somech
Journal:  Clin Exp Immunol       Date:  2017-06-05       Impact factor: 4.330

6.  Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.

Authors:  David Millrine; Mami Tei; Yohannes Gemechu; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 7.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

Review 8.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 9.  Somatic mutagenesis in autoimmunity.

Authors:  Thiago Detanico; James B St Clair; Katja Aviszus; Greg Kirchenbaum; Wenzhong Guo; Lawrence J Wysocki
Journal:  Autoimmunity       Date:  2013-01-18       Impact factor: 2.815

Review 10.  Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.

Authors:  Lindsey A George; David T Teachey
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.